CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

Exclusion Criteria

• •patients with recurrence of only isolated extramedullary lesions.
• •combination of other malignant tumors.
• •previously treated with anti-CD19 or/and CD22 or/and CD3 therapies.
• •immunosuppressants use within 2 weeks prior to signing informed consent or plan to immunosuppressants after signing informed consent.
• •uncontrolled active infections.
• •HIV infection.
• •active hepatitis B or hepatitis C infection.
• •history of severe tachyphylaxis to aminoglycoside antibiotics.
• •history or presence of clinically relevant Central Nervous System (CNS) pathology, such as epilepsy, generalized seizure disorder, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.